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Summary
Objective: To validate flow cytometry as an experimental technique for the study of the homeostasis of the extracellular matrix (ECM) of
human articular cartilage.
Methods: Given the established insights in the relation between the transforming growth factor (TGF)- type II Receptor (TGF-RII)/TGF-
auto/paracrine pathway, the intracellular levels of matrix metalloproteinases (MMPs) and their natural inhibitors (TIMPs), and the
accumulation of ECM molecules in the ECM of articular cartilage, this metabolic pathway was used as a reference model to fulfill the
objective. Chondrocytes were liberated from visually intact femoral condyle cartilage and cultured in gelled agarose to maintain their
differentiated phenotype. After 2 weeks of culture, the chondrocytes were isolated from the agarose and flow cytometry was used to analyse
the expression of TGF-RII on the plasmamembrane, the expression of TGF1, MMP-1, MMP-3, TIMP-1 and TIMP-3 inside the cells, as well
as the amounts of aggrecan, type II collagen and hyaluronan in the cell-associated matrix (CAM). The expression of the different substances
was analysed with flow cytometry and reported as mean fluorescence intensity (MFI), which is due to the binding of FITC-labeled antibodies
to their specific antigens. In addition, the effects of exogenous TGF1 on the expression of these proteins was investigated on chondrocytes
cultured in serum-free media. Enzyme Linked Immunosorbent Assay (ELISA) was performed to evaluate the MMP-1, MMP-3, TIMP-1 and
MMP-1/TIMP-1 complex in the culture medium collected after the last 3 days of the culture period. The correlations between the data were
analysed with the Spearman’s test.
Results: Exogenous TGF-1 increased the accumulation of aggrecan and hyaluronan in the CAM of chondrocytes and down-regulated the
intracellular levels of MMP-1 and -3. TIMP-1 and -3 were increased after exposure to TGF-1. Baseline expression of TGF-RII on the
plasmamembrane of normal human articular chondrocytes significantly correlated with the intracellular levels of TGF1, TIMP-1 and TIMP-3.
TGF1 was correlated with TIMP-1, TIMP-3 and MMP-1. Aggrecan in the CAM was inversely correlated with the ratio of MMP-1 to TIMPs.
In addition, there were correlations between TIMP-1 and TIMP-3, aggrecan and hyaluronan. ELISA also revealed the correlation between
MMP-1 and TIMP-1 secreted by the chondrocytes into the nutrient medium. MMP-1/TIMP-1 complex was hardly found in the medium.
Conclusions: Some aspects of ECM metabolism of normal cartilage were evaluated by flow cytometry. Chondrocytes from normal human
cartilage, when cultured in gelled agarose, showed correlations between the expression of TGF-RII/TGF-1 and the intracellular levels of
TIMPs, indicating that TGF- autocrine pathway may contribute to homeostasis of the ECM in the normal cartilage. The relations between
MMPs, TIMPs and the ECM molecules support that a physiological balance between MMPs and TIMPs results in a well-controlled matrix
turnover in normal cartilage. © 2002 OsteoArthritis Research Society International
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The potential role of transforming growth factor (TGF)-
in the control of both cartilage homeostasis and repair
has been extensively explored over the recent years. It
has been established that TGF- affects chondrocyte
metabolism in regulating cell proliferation as well as extra-
cellular matrix (ECM) synthesis. TGF- was also shown to
counterbalance the effects of IL-1 and may thus help
chondrocytes to restore the ECM in osteoarticular
diseases1,2. TGF is rather unique amongst the growth
factors in that it modulates enzyme release from various
cell types and that it enhances the production of enzyme188inhibitors3–5, and therefore is considered as an important
feedback regulator of connective tissue repair.
Normal and abnormal extracellular matrix turnover is
thought to result, in part, from the balance in the expression
of matrix metalloproteinases (MMPs) and tissue inhibitors
of metalloproteinases (TIMPs). The group of MMPs con-
sists of collagenases (MMP-1, -8 and -13), gelatinases
(MMP-2 and -9), stromelysins (MMP-3, -10 and -11) and
membrane-type MMPs. They act at neutral pH and are the
main enzymes involved in the degradation of cartilage
matrix components6,7. MMPs are secreted in a latent form
as proenzymes8. Recently, a disintegrin and metallo-
proteinase with thrombospondin motifs that possesses
aggrecanase activity: ADAMTS49 has been identified as a
key aggrecan degrading activity in pathological cartilage10.
Under physiological conditions, specific inhibitors such as
the family of TIMPs regulate these enzymatic activities6,8.
The TIMP family consists of TIMP-1, -2, -3 and -4. While
TIMP-1 is secreted in body fluids, TIMP-3 is distinctly
located in ECM. TIMP-3 inhibits MMPs to the same extent
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ISOLATION OF CHONDROCYTES
Human articular chondrocytes were isolated as
described elsewhere19,20, with a few modifications21.
Articular cartilage was obtained at autopsy from 11 donors
(9 males, 2 females, age range 24–74 years) within 24 h
post mortem. All donors had died after a short illness and
had not been receiving corticosteroids or cytostatic drugs.
Visually intact cartilage was sampled from the femur con-
dyles, diced in small fragments and digested in a spinner
bottle with a series of enzymatic solutions in Dulbecco’s
modified Eagle’s medium (DMEM; GIBCO BRL, Grand
Island, NY) with 0.002M/ml L-glutamine and antibiotics and
antimycotics (GIBCO BRL). Cartilage was first treated with
0.25% (w/v) of sheep testes hyaluronidase (Sigma,
St. Louis, MO, U.S.A.) for 120 min and 0.25% of Pronase
(Streptomyces griseus Pronase E; Sigma) for 90 min at
37°C. After an overnight period in DMEM supple-
mented with 10% fetal calf serum (FCS, GIBCO BRL), a
3–6 h incubation with 0.25% collagenase (Clostridiumhistolyticum; Sigma) in DMEM containing 10% FCS at 37°C
resulted in the liberation of isolated cartilage cells. Usually,
150×106 chondrocytes could be obtained from femoral
condyles of one individual and over 95% of the cells were
viable (Trypan Blue exclusion test) after isolation.CHONDROCYTES IN AGAROSE CULTURE
Chondrocytes were cultured in gelled agarose as pre-
viously described22 with some modifications21,23. Chondro-
cyte suspension cultures were established in 1.5% agarose
(ultralow gelling temperature agarose, Sigma) in 3.8 ml
cryotubes (Nunc). Coated cryotubes were filled with 300 l
of chondrocytes/agarose suspension and kept at 4–8°C for
15 min to allow the agarose to gel. The final cell density
was approximately 1.0×106 chondrocytes per culture. The
cultures were filled with 3 ml DMEM containing 10% FCS
and 50 g/ml of freshly dissolved ascorbate, and placed in
an incubator at 37°C under 5% CO2. Nutrient media were
replaced twice a week. After 2 weeks, the final 3-day spent
incubation media were aspirated and stored at −20°C for
further use. Cells were prepared for flow cytometry.EFFECT OF EXOGENOUS TGF-1 ON THE EXPRESSION OF CAM
MOLECULES AND ON INTRACELLULAR MMPS AND TIMPS
Chondrocytes were obtained from a 34-year-old
male and cultured in agarose. Serum-free medium (DMEM
supplemented with 0.5% bovine albumin (Sigma) and
100 ng/ml bovine pancreas insulin (Roche Molecular Bio-
chemicals, Mannheim, Germany) was used as described24.
TGF-1 (R&D Systems) was added at 0, 10 and 50 ng/ml
concentrations. Medium was replaced every 3 days.
After 8 days of culture, chondrocytes were harvested to
assess CAM aggrecan, hyaluronan, type II collagen, and
intracellular levels of MMP-1, -3, -13, TIMP-1 and -3.PREPARATION OF CHONDROCYTES FOR FLOW CYTOMETRY
Samples of isolated chondrocytes with their CAM were
obtained from cultures after agarase digestion of the gelled
agarose as previously described25,26. TGF-RII on the cell
membrane, and aggrecan and type II collagen in the CAM
were tested directly after incubation with the appropriate
antibodies for 30 min in the dark at 4°C. 20 l of 50 g/ml
FITC-labeled antibodies were used to react with 2×105
cells resuspended in 100 l PBS. To test hyaluronan,
2×105 cells in 100 l PBS were first incubated with 20 l of
50 g/ml biotinylated hyaluronic acid binding protein
(bHABP) for 30 min. After washing the cells with PBS, 4 l
avidin-FITC was added for another 30 min incubation at
4°C in the dark.
In order to evaluate the expression of TGF1, MMP-1,
MMP-3, TIMP-1 and TIMP-3 inside the cells, chondrocytes
were permeabilized using Cytofix/Cytoperm Plus Kit
(PharMingen, San Diego, CA, U.S.A.) according to the
manufacturer’s instruction. Briefly, cells in culture were
incubated with monensin (GolgiStop, 4 l/6 ml medium)
for 5 h to block the protein transport from Golgi apparatus.
Cells isolated from agarose were permeabilized using
Cytofix/Cytoperm solution for 15 min. After a wash in 1×
Perm/Wash solution, the procedure was followed by the
incubation with monoclonal antibodies (Mabs).as TIMP-111. The clinical manifestations of an imbalance
between tissue degrading enzymes and their inhibitors
are evident in a variety of pathologic states, in which
inadequate cartilage ECM repair is obvious12–14. TGF-1
has been shown to modulate the synthesis and secretion of
proteinases and to up regulate TIMP-1 expression in
human and bovine articular cartilage4,5.
Biological effects of TGF- are correlated with its binding
to specific receptors. TGF- signals through heteromeric
type I and type II serine/threonine kinase receptors.
The current model for TGF- receptor activation is that the
type II receptor binds to its ligand and then recruits type I
receptor to form a heteromeric complex. The type II
receptor (TGFRII) phosphorylates and activates the type I
receptor kinase which transmits the signal to the nucleus15.
In this study, we focused on the relation between
TGFRII/TGF-, the MMP/TIMP system, and some ECM
molecules in the cell-associated matrix (CAM) of normal
human chondrocytes in vitro in order to validate flow
cytometry as an experimental technique for the study of the
homeostasis of the ECM of human articular cartilage.
The CAM is a constant part of the ECM16,17 of which the
macromolecular compounds are metabolized or turned
over in a particular way18. Flow cytometry offers the possi-
bility to study the expression of a series of intracellular,
plasmamembrane, and cell-associated matrix molecules
on well-defined populations of cells. Any epitope, against
which a specific antibody can be raised, can be investi-
gated. The cells can be selected on the presence or
absence of physiologically interesting characteristics, e.g.
the expression of receptors for growth and differentiation
factors, or the presence of CAM compounds. Different
molecules can be simultaneously tested for the presence of
any other factor. The technique is less laborious than when
a spectrum of biochemical techniques is used and the
results are expressed in a quantitative way.
Flow cytometry was used to analyse TGFRII on the cell
membrane, the intracellular levels of TGF1, MMP-1 and
-3, TIMP-1 and -3, and the presence of aggrecan, type II
collagen and hyaluronan in the CAM. Enzyme Linked
Immunosorbent Assay (ELISA) measured the secretion of
MMPs and TIMPs from the chondrocytes into the culture
medium.
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FITC-conjugated rabbit anti-human TGF-RII polyclonal
antibody and the rabbit IgG negative control were pur-
chased from Santa Cruz Biotechnology, INC (Santa Cruz,
CA, U.S.A.). Mabs against TGF-1 (clone 9016.2) and
MMP-1 (clone 36665.111) were bought from R&D systems
(Abingdon, U.K.). Mabs against MMP-3 (clone 55-2A4),
TIMP-1 (clone 7-6C1) and TIMP-3 (clone 136-13H4) were
obtained from Oncogene Research Products (Boston, MA,
U.S.A.). MMP-1 antibody was against both pro- and active
form of MMP-1. MMP-3 antibody recognized latent and
active MMP-3 and reacted with MMP-3/TIMP-1 complexes.
TIMP-1 antibody reacted with free TIMP-1 and MMP/
TIMP-1 complexes. The anti-TIMP-3 recognized both gly-
cosylated and unglycosylated TIMP-3. Mouse antihuman
chondrocyte-specific aggrecan Mab (clone 4D11-2A9, Bio-
source Europe, Nivelles, Belgium) was shown to react
specifically with the G1-domain of the invariable
hyaluronan-binding region of the human aggrecan mol-
ecule, and was used to detect the aggrecan in the chondro-
cyte CAM. Mouse antihuman type II collagen Mab (clone
II-4C11, ICN Biochemicals, Ohio, U.S.A.) was chosen to
detect type II collagen. All the antibodies (except TGFRII)
were conjugated with FITC (Fluorescein isothiocyanate,
Isomer I, Sigma) as previously described25 and used in a
direct immunofluorescent staining protocol for flow
cytometry. FITC-labeled isotype matched mouse IgG1
(Becton Dickinson) was used as a negative control.
Biotinylated hyaluronic acid binding protein (bHABP)
was a kind gift from Dr J. Melrose (Raymond Purves
Research Laboratories, University of Sidney, Australia) and
was used to trace hyaluronan in the CAM. Binding of
bHABP to hyaluronan in the CAM was followed by a
second-step avidin-FITC (Becton Dickinson) staining.FLOW CYTOMETRIC ANALYSIS
Stained cells were analysed on a flow cytometer
(FACSort, Becton Dickinson, San Jose, CA, U.S.A.) with
CELLQuest software. From each sample, 15,000 events
were analysed. Cells were gated on forward and side
scatter to exclude dead cells, debris and aggregates. Pro-
pidium iodide was additionally used to exclude dead cells
when the epitopes outside the cells, i.e. TGFRII and ECM
molecules, were analysed21,22. The MFI of the positive cell
population, which is due to the binding of the FITC-labeled
antibodies to the specific antigen, was used to quantify the
presence of TGF-RII on the plasmamembrane, the ECM
molecules in the CAM, and the accumulation of TGF-1,
MMP-1, MMP-3, TIMP-1 and TIMP-3 in the cells.
For comparison between experiments (except for the
analysis of TGFRII and hyaluronan), Quantum Simply
Cellular Microbead Kit (Sigma) was used to calibrate the
fluorescence scale of the flow cytometer. The product
contains a mixture of four uniform microbead populations,
which differ by their incremental capacities to bind mouse
IgG. The microbeads were stained and processed in par-
allel with the cell samples using the same amount of
FITC-labeled antibodies and incubation time. Four peaks
standing for the four microbead populations represented
stained microbeads. The fluorescence scale of the cytom-
eter was adapted before every experiment in order to keep
identical MFIs for the four peaks of the calibration beads
(Fig. 1). The MFI of cell samples was then analysed without
changing any instrument settings.In order to exclude the possibility that cell bound matrix
molecules impair the detection of cell membrane antigens
(e.g. TGFRII), a series of chondrocytes was pre-treated
with 5 units/ml hyaluronate lyase (Streptomyces Hyaluro-
lyticus, Sigma) in PBS for 1 h at 37°C prior to labeling with
TGFRII-FITC. TGFRII chondrocyte MFI after removal of
the CAM aggrecan/HA complexes was compared with
TGFRII MFI of untreated chondrocytes.0
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Fig. 1. Calibration of the fluorescence scale of the flow cytometer.
(a) Representative flow cytometry histogram for calibration beads
showing the four peaks due to four populations of beads with
different antibody binding capacity. Ordinate: Bead counts;
Abscissa: Fluorescence intensity. (b) The relation of the mean
fluorescence intensity (MFI) of the four peaks to the antibody
binding capacity (ABC) of the four populations of beads.MEASUREMENT OF MMPS AND TIMPS IN THE MEDIUM
After the 2-week culture period, the last spent incubation
media from the last 3 days were collected for the analysis
of secreted MMP-1, MMP-3, TIMP-1, MMP-1/TIMP-1 com-
plex using an enzyme linked immunosorbent assay
(ELISA) method.
MMP-1 and MMP-3 were tested using the BIOTRAK-
ELISA-System (Amersham Int., Little Chalfont, U.K.). The
ELISA for MMP-1 recognized human total, i.e. free MMP-1
and MMP-1 bound to TIMP-1, but not MMP-1 bound to the
non-specific proteinase inhibitor 2-macroglobulin. Its sen-
sitivity was determined at 1.7 ng/ml. The ELISA for MMP-3
was specific for free MMP-3, proMMP-3, and MMP-3/TIMP
complexes. The sensitivity of this assay was determined at
2.35 ng/ml.
TIMP-1 and MMP-1/TIMP-1 complex were tested using
ELISA Kits from Oncogene Research Products (Boston,
MA, U.S.A.). The minimum dose of TIMP-1 protein detect-
able in this assay was less than 0.0096 ng/ml. The ELISA
Osteoarthritis and Cartilage Vol. 10, No. 3 191for TIMP-1 was specific for free TIMP-1 as well as for
complexed TIMP-1. Furthermore, the MMP-1/TIMP-1 com-
plex was measured independently. The ELISA for the
MMP-1/TIMP-1 complex did not detect free MMP or TIMP.
The minimum dose of MMP-1/TIMP-1 complex detectable
in this assay was less than 0.020 ng/ml. All the assays were
performed as described in the manufacturer’s instructions.STATISTICAL ANALYSIS
Mean values and Standard Deviations of the MFI values
and ELISA contents were calculated from triplicate cell
cultures. Medians and ranges for the different variables
obtained from the donors were represented. The correla-
tions between the mean values of different parameters
were performed with the Spearman’s test. Student’s t-tests
were used to examine whether variables were signifi-
cantly different in the TGF- treated chondrocyte cultures.
Significance levels for all tests were set at P=0.05.ResultsCHONDROCYTE MFI DUE TO PLASMAMEMBRANE ANTIGEN IS NOT
SUPPRESSED BY THE PRESENCE OF THE CAM
Chondrocyte MFI for TGFRII did not increase after
exposure of the chondrocytes to Streptomyces Hyaluro-
lyticus hyaluronidase while this enzyme was shown to
completely remove aggrecan from the cellbound matrix
(Table I).EFFECT OF EXOGENOUS TGF-1 ON THE EXPRESSION OF CAM
MOLECULES AND ON INTRACELLULAR MMPS AND TIMPS
Both 10 and 50 ng/ml concentrations of TGF-1
increased the accumulation of aggrecan and hyaluronan in
the CAM and down-regulated the intracellular levels of
MMP-1 and -3. Intracellular TIMP-1 and -3 were increased
after exposure to 50 ng/ml TGF-1. No significant changes
of type II collagen and MMP-13 were observed (Fig. 2).EXPRESSION OF DIFFERENT ANTIGENS IN CHONDROCYTE
CULTURES
Expression of different antigens was quantified using
chondrocyte MFI values after staining with the respective
specific FITC-labeled antibodies (Fig. 3). Median values
for each parameter and their ranges are summarized in
Table II. The mean values of triplicate samples of each
donor showed coefficient of variation values less than
20%.
The MFI reflecting the TGFRII on the cell membrane
ranged from 7.9 to 19.1, with a median of 8.7. TGF-1,
MMP and TIMP levels inside the cells, which directly
indicate their production by the chondrocytes, were
analysed after permeabilization of the cells. The values for
these items varied widely through the nine donors. Median
chondrocyte MFIs for MMP-3 and TIMP-1 were relatively
high, 89.0 and 39.4, respectively. The median chondrocyte
MFI for TGF-1, MMP-1 and TIMP-3 were 25.5, 19.9 and
18.4, respectively.
The accumulation of ECM molecules in the CAM agreed
with previous observations25,26. The median chondrocyte
MFI for aggrecan, type II collagen and hyaluronan in the
CAM were 242.1, 10.9 and 19.8, respectively.
In order to evaluate the balance of MMP and TIMP, their
chondrocyte MFI ratios were calculated separately. The
median MFI ratio for MMP-1 to TIMP-1 plus TIMP-3, and
MMP-3 to TIMP-1 plus TIMP-3 were 0.30 and 0.90,
respectively.Table I
Effect of enzymatic removal of CAM aggrecan on the detection of
cell membrane TGFRII (MFI)
Aggrecan TGFRII
Control cells 282.6±31.0 17.9±1.7
5 U/ml hyaluronate lyase treated cells 6.6±0.5 17.5±2.0
Donor: M62; mean MFI values ±1 standard deviation are given.0
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Fig. 2. Effect of 10 and 50 ng/ml concentrations of TGF-1 on the expression of CAM molecules and on intracellular MMPs and TIMPs.
Ordinate: mean fluorescence intensity of the cell population. BSA: bovine serum albumin. *: Level of significance P<0.05. BSA+insulin,
; BSA+insulin+TGF-1 (10 ng/ml), ; BSA+insulin+TGF-1 (50 ng/ml), .MMP AND TIMP ACTIVITIES IN SPENT INCUBATION MEDIA
MMP-1, MMP-3, TIMP-1 and MMP-1/TIMP-1 complex
secreted into the culture medium were assayed by ELISA.
192 L. Wang et al.: TGF- and cartilage extracellular matrix homeostasisAfter 2 weeks of culture, the spent media of the last 3 days
of culture from 10 donors were collected. Medium samples
from 3 chondrocyte cultures obtained from each donor
were analysed. The range and median values of the
average concentrations of triplicate samples are listed in
Table III.
The median values for the contents of MMP-1, MMP-3
and TIMP-1 were 10.74, 1021.30 and 115.52 ng/ml,
respectively. The content of MMP-1/TIMP-1 complex was
extremely low. In seven of the 10 donors, MMP-1/TIMP-1
complex levels in the chondrocyte culture media were
below the detectable limit of 0.11 ng/ml. Complex levels in
the chondrocyte culture media of the other three donors
were 0.201, 0.779 and 1.979 ng/ml, respectively.THE CORRELATIONS BETWEEN THE DIFFERENT PARAMETERS
Correlations between the TGFRII expression on the cell
membrane, TGF-1, MMP and TIMP levels inside the cells
and the accumulation of CAM molecules are shown in
Table IV (N=9). TGFRII significantly correlated with
TGF-1 (r=0.721, P=0.04), TIMP-1 (r=0.829, P=0.02) and
TIMP-3 (r=0.762, P=0.03). In addition, there was border-
line significant correlation between TGFRII and the pres-
ence of type II collagen in the CAM (r=0.679, P=0.05).
Besides TGFRII, TGF-1 strongly correlated with TIMP-1
(r=0.933, P=0.01), TIMP-3 (r=0.933, P=0.01) and MMP-1
(r=0.917, P=0.01). Correlations were observed between
intracellular MMP-1 and TIMP-1 (r=0.817, P=0.02),
MMP-1 and TIMP-3 (r=0.867, P=0.01), and TIMP-1 and
TIMP-3 (r=0.900, P=0.01). In the CAM, as expected,
aggrecan was significantly correlated with hyaluronan
(r=0.783, P=0.03). Interestingly, aggrecan was inversely
correlated with the ratios of MMP-1 to TIMP-1 plus TIMP-3
(r= −0.733, P=0.04).In the spent culture media (N=10), there were correla-
tions between the concentrations of MMP-1 and TIMP-1
(r=0.818, P=0.01), and MMP-1 and MMP-3 (r=0.673,
P=0.01) (Table V). The secreted MMPs and TIMP-1 did not
correlate with their intracellular levels as tested with flow
cytometry, neither with the expression of TGFRII, TGF-1
and the ECM molecules by the chondrocytes (Table V).100 101 102 103 104
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Fig. 3. Representative analytical flow cytometry histograms (Donor M74). (a) Expression of TGFRII on the cell membrane. (b–f) Expression
of TGF1, MMP-1, MMP-3, TIMP-1 and TIMP-3 inside the cells. Left curves: negative controls; Right curves: antibody-labeled chondrocytes.
Ordinate: cell numbers; Abscissa: Fluorescence intensity.Discussion
Turnover of the ECM is well controlled in normal cartilage
where enzymes and their inhibitors, and growth factors and
catabolic cytokines are balanced27. TGF- is a major
growth factor known to promote the synthesis of type II
collagen and aggrecan, whereas cytokines like IL-1
inhibit cartilage matrix synthesis and promote cartilage
destruction.
Recent studies have illustrated the importance of
TGFRII in the maintenance of normal cartilage structure
and function. The expression of TGFRII has been found
dramatically reduced to barely detectable levels in the
fibrillated cartilage of the rabbit OA model28, and it was
reported that transgenic mice expressing a truncated,
kinase-defective TGFRII developed a degenerative joint
disease resembling human OA29. Scharstuhl et al. reported
that cartilage PG content was lower in soluble TGFRII
treated mice than in control animals, suggesting that TGF-
activity blocked by TGFRII results in a decreased PG
tissue content30. These observations support that cartilage
destruction is accompanied by a progressive reduction of
chondrocyte responsiveness to TGF-. Down-regulation
of TGFRII probably results in reduced sensitivity of
the chondrocytes to TGF- during the development of
degenerative joint disease.
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Concentrations (ng/ml) of MMP-1, MMP-3, TIMP-1 and MMP-1/TIMP-1 complex in the culture media
MMP-1 MMP-3 TIMP-1 MMP-1/TIMP-1 complex
M39 18.90±1.12 1938.20±48.51 163.40±22.61 0.201±0.124
M62 10.95±0.12 1175.15±98.64 131.14±14.88 0.779±0.065
M61 7.02±0.69 867.45±64.34 93.86±30.65 <0.11
F62 10.53±1.70 507.10±9.05 138.87±0.89 <0.11
M59 7.35±1.69 660.73±80.42 79.13±3.73 <0.11
M55 6.86±0.41 1224.10±58.12 78.04±12.96 <0.11
F65 12.02±0.60 799.50±116.1 112.10±13.81 <0.11
M58 21.59±3.20 1272.50±44.96 118.94±7.17 <0.11
M74 6.37±1.52 346.53±98.59 76.23±7.21 <0.11
M24 27.64±13.71 1745.50±22.34 160.71±37.20 1.979±0.650
Range 6.37–27.64 346.53–1938.20 76.23–163.40 <0.11–1.979
Median 10.74 1021.30 115.52 —
Donor: sex/age; mean values ±1 standard deviation of the concentration are given.Table IV
Correlations between TGFRII expression on the cell membrane, TGF-1, MMPs and TIMPs inside the cells, and ECM molecules located
in the CAM (N=9)
TGFRII TGF-1 MMP1 MMP3 TIMP1 TIMP3 Aggrecan Collagen II Hyaluronan
TGF-1 0.721
(0.04)
MMP-1 0.496 0.917
(0.01)
MMP-3 0.304 0.500 0.600
TIMP-1 0.829 0.933 0.817 0.567
(0.02) (0.01) (0.02)
TIMP-3 0.762 0.933 0.867 0.667 0.900
(0.03) (0.01) (0.01) (0.01)
Aggrecan 0.488 0.000 −0.150 0.083 0.250 0.000
Collagen II 0.679 0.467 0.450 0.117 0.550 0.500 0.383
(0.05)
Hyaluronan 0.196 −0.267 −0.250 0.117 −0.083 −0.067 0.783 0.467
(0.03)
MMP1/TIMP1+TIMP3 −0.121 0.400 −0.733 −0.083 −0.617
(0.04)
MMP3/TIMP1+TIMP3 −0.387 −0.550 −0.117 −0.500 0.617
Values are the correlation coefficients (r). P values with significant levels are given between brackets.Degradation of the cartilage matrix is thought to be the
consequence of increased activity of several groups of
enzymes, which can be produced by chondrocytes. Char-
acteristically, MMP-1 (collagenase-1) and MMP-3
(stromelysin-1) have been found increased in osteoarthritic
cartilage31,32 and in the synovial fluid of osteoarthritic
joints33–35. More recently, MMP-8 (collagenase-2) and
MMP-13 (collagenase-3) have been described as two of
the main collagen degrading activities in OA cartilage36–38.
Aggrecanase is the most prominent aggrecan degrading
activity when pathological (OA) cartilage samples were
investigated10. Treatment with IL-1, TNF or retinoic acid
was specifically required to get the enzyme expressed
in vitro on explant cultures and evidence supports that
aggrecanase activity in these systems precedes MMP
cleavage of aggrecan39–42.
Naturally occurring endogenous inhibitors of MMPs,
TIMPs, were expressed in normal cartilage and have been
found over-expressed in degenerative joints. Over-
expression of TIMPs in the ECM in OA cartilage does not
imply that MMPs are kept completely inactive. The sub-
strates for MMP in the ECM also are present in extraordi-
narily high concentrations and the linear enzyme kinetics
obtained in experimental enzymology are not achieved inthe ECM or in the CAM. However, TIMPs, are considered
as important controlling factors in the actions of MMPs, and
TIMP-1 and -3 have been shown to inhibit aggrecanase
activity in IL-1 or retinoic acid treated bovine nasal cartilage
explants41–44.
Tissue destruction in disease processes often correlates
with an imbalance of MMPs over TIMPs. The pathophysi-
ological and biological significance of TIMPs was investi-
gated in normal and osteoarthritic human joint tissues6, the
two main joint tissues, synovial membrane and cartilage,
express TIMP genes. TIMP-1 mRNAs were low or unde-
tectable in human fetal chondrocytes but were expressed
at all other ages32. TIMP-1 and -3 mRNAs were elevated in
most human OA synovia over controls, while TIMP-2
expression was similar32. TGF- induced TIMP-1 and -3
mRNA and protein in human OA chondrocytes32,45. Due to
their matrix protecting activities, the presence of multiple
TIMPs may be beneficial for normal joints, while increased
TIMP-3 and TIMP-1 expression in arthritic joints may be
associated with pathological remodeling.
In order to validate flow cytometry as a tool to study ECM
metabolism by chondrocytes in normal human articular
cartilage, this study focused on the relation between the
TGF/TGFRII pathway and the MMP-1,3/TIMP-1,3
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Correlations between MMP-1, MMP-3 and TIMP-1 concentrations
in the nutrient media (N=10). Comparison with flow cytometric
findings (N=9)
MMP-1* MMP-3* TIMP-1*
MMP-3* 0.673
(0.04)
TIMP-1* 0.818 0.588
(0.01)
MMP-1 0.033
MMP-3 −0.033
TIMP-1 −0.117
TGFRII 0.404 0.088 0.129
TGF-1 0.083 −0.117 −0.383
Aggrecan 0.150 −0.317 0.217
Type II collagen 0.250 0.217 0.133
Hyaluronan 0.050 −0.017 0.133
Correlation coefficients (r) are given; P values with significant
levels are given between brackets; * Results of ELISA.system in the regulation of cartilage type II collagen and
aggrecan turnover.
Chondrocytes obtained from human normal articular
cartilage were cultured in gelled agarose to maintain their
differentiated phenotype. Two-week culture allowed the
cells to reach equilibrium in accumulated CAM compounds
and cell numbers25,46. The agarase digestion of the agar-
ose gel has been shown not to influence the detection of
matrix molecules around the cell and epitopes on the
membrane25. The detection of TGFRII on the plasma-
membrane was not hampered by the presence of
aggrecan/HA complexes in the chondrocyte pericellular
matrix. Immunofluorescent staining previously allowed
MMPs and TIMP-1 to be detected as bright intracellular
accumulations within Golgi vesicles when studied in articu-
lar cartilage47, and this enabled us to analyse the antigen
accumulation in the cell using flow cytometry after fixation
and permeabilization of the chondrocytes.
Our flow cytometry assays have shown that the expres-
sion of TGFRII on the chondrocyte cell membrane signifi-
cantly correlated with the intracellular levels of TGF-1,
some of the MMPs and their natural inhibitors TIMP-1 and
-3, and the CAM protein levels. In addition, there was a
borderline significant correlation between TGFRII and the
presence of type II collagen in the CAM. These experimen-
tal data illustrate how TGF- and its receptor contribute
to the homeostasis of the extracellular matrix in normal
articular cartilage through an autocrine/paracrine pathway.
The results obtained indicate a co-expression of some
MMPs and their natural inhibitors in chondrocytes, support-
ing a physiological balance between MMPs and their inhibi-
tors where the homeostasis of the ECM in normal
physiological conditions is concerned.
Measurement of MMP-1 and TIMP-1 in the spent nutri-
ent media confirmed their balanced secretion by the
chondrocytes. MMP-1 was also correlated with MMP-3 in
the medium, suggesting their coordinate secretion from
chondrocytes. MMP-1 levels were much lower than those
of MMP-3, confirming the reports that articular cartilage,
rather than synovium, is the major source of MMP-312.
TIMPs are known to inhibit MMPs by forming 1:1 molar
ratio complexes. The low or undetectable levels of MMP-1/
TIMP-1 complex in the nutrient media indicate the low
activation of MMP-1 in healthy cartilage.Furthermore, the ratio of MMP-1 to the sum of TIMP-1
and TIMP-3 was inversely correlated with the accumulation
of aggrecan in the CAM, indicating that the matrix turnover
is, at least in part, the result of the regulation of MMP/TIMP
system. In addition, the intracellular levels of the both
TIMPs closely agreed, showing probably a coordinate
production. Flow cytometric analysis of the CAM revealed a
coordinate accumulation of hyaluronan and aggrecan in the
pericellular matrix.
Both TGFRII and its ligand were correlated with TIMP-1
and TIMP-3 inside the cells. The finding of a correlation
between TGF- and TIMPs makes sense, since TIMPs also
have growth factor activities48,49. TIMPs may promote cell
growth and so play a role in repair processes. TGF-1 was
reported to induce TIMP expression in articular chondro-
cytes3,32. Therefore, it is suggested that the chondrocyte
TGFRII/TGF-1 pathway indirectly controls the contents
of the ECM through the TIMP system and that any situation
inducing ECM degradation, e.g. inflammatory events or
mechanical damage, will activate a TGF-/TIMP response
resulting in a new equilibrium.
A number of our observations on ECM homeostasis may
seem unexpected and need further consideration. Even
though TGF-1 was found to be essential to maintain
aggrecan synthesis rates by chondrocytes in serum-free
culture conditions24, no correlation was found between
chondrocyte TGFRII/TGF-1 and CAM aggrecan. The
fact that MMPs were high in chondrocytes expressing
functional TGF- autocrine pathways may be confusing
and seem in conflict with earlier reports in chondrocytes50
and in fibroblasts51–53 where TGF- has been shown to
depress MMP-1, -2 and -3. Furthermore, a functional
TGFR/TGF- pathway has been shown to increase
MMP-13 in connective tissue cells50,54 and high local
MMP-13 levels thus should decrease CAM collagen. In our
experiments, however, flow cytometry showed high intra-
cellular TGF- levels to correlate with high amounts of type
II collagen in the CAM. Such discrepancies may even
indicate a defect of the flow cytometry technique.
To evaluate ECM metabolism and turnover by chondro-
cytes by looking at homeostasis of the ECM, or by perform-
ing cause/effect experiments, are two completely different
approaches of which the results provide complementary
information.
The proportions of and the relationships between
epitopes (ECM molecules, receptors, etc.) in a matrix in
equilibrium (homeostasis) depend on a series of known
and unknown factors. These relations cannot always be
predicted by cause/effect experiments where only a
selected number of well-specified controlling factors are
included.
This is well illustrated when the effects of exogenous
TGF- on intracellular MMP/TIMP levels and subsequent
aggrecan accumulation in the CAM were studied in a
serum-free incubation medium. This experiment was con-
ducted on one single donor and not repeated since the
agreement with current literature data was complete. It was
shown that TGF- decreased MMP-1 and 3, and
up-regulated TIMP inside the cells. In these cells, an
increase accumulation of aggrecan in the CAM was seen.
This observation proves that there is no defect of the flow
cytometry technique and validates this experimental assay
method.
On the other hand, the finding of a correlation between
TGF- and MMP in an ECM in equilibrium does not
disagree with the results obtained in the cause/effect exper-
iment, or with the literature data. The originality of a study
196 L. Wang et al.: TGF- and cartilage extracellular matrix homeostasison homeostasis of the ECM by chondrocytes lies in the
fact that this approach illustrates how other factors than
TGF- probably are involved in the control of intra- and
extracellular MMP and TIMP in an ECM at equilibrium.
In summary, being responsible for TGF- signal trans-
duction, TGFRII on the chondrocyte cell membrane was
closely associated with the autocrine production of TGF-.
Both of the ligand and receptor correlated well with intra-
cellular TIMP levels. Therefore, the TGF- autocrine path-
way may result in the maintenance of a balanced MMP/
TIMP system in normal cartilage, and contributes to the
turnover of the cartilage matrix in physiological conditions.
Flow cytometry offers a technique to investigate the influ-
ence of growth and differentiation factor and cytokine
cascades on the synthesis and degradation of a variety
of extracellular matrix components. Comparative studies
on chondrocytes obtained from normal and osteoarthritic
cartilage are in progress.References
1. Pujol JP, Gale´ra P, Pronost S, Boumediene K, Vivien
D, Macro H, et al. Transforming growth factor-
(TGF-) and articular chondrocytes. Ann Endocrinol
1994;55:109–20.
2. Redini F, Guerra P, Mauve A, Loyal G, Pool JP.
Transforming growth factor  stimulates collagen and
glycosaminoglycan biosynthesis in cultured rabbit
articular chondrocytes. FEBS Lett 1988;234:172–6.
3. Gunther M, Haubeck HD, van de Leur E, Blaser J,
Bender S, Gutgemann I, et al. TGF1 regulates
tissue inhibitor of metalloproteinase-1 expression in
differentiated human articular chondrocytes. Arthritis
Rheum 1994;37:395–405.
4. Wright JK, Cawston TE, Hazleman BI. TGF stimu-
lates the production of the tissue inhibitor of metallo-
proteinases (TIMP) by human synovial and skin
fibroblasts. Biochem Biophys Acta 1991;1094:
207–10.
5. Edwards DR, Murphy G, Reynolds JJ, Whitham SE,
Docherty ALP, Angel P, et al. Transforming growth
factor beta modulates the expression of collagenase
and metalloproteinase inhibitor. EMBO J 1987;6:
1899–904.
6. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS,
Woessner JF Jr. Evidence for metalloproteinase
and metalloproteinase inhibitor imbalance in human
osteoarthritic cartilage. J Clin Invest 1989;84:678–85.
7. Pelletier JP, Mineau F, Faure MP, Martel-Pelletier J.
Imbalance between the mechanisms of activation
and inhibition of metalloproteinases in the early
lesion of experimental osteoarthritis. Arthritis Rheum
1990;33:1466–76.
8. Matrisian LM. Metalloproteinases and their inhibitors in
matrix remodeling. TIG 1990;6:121–3.
9. Tortorella MD, Burn TC, Pratta MA, Abbaszade I, Hollis
JM, Liu R, et al. Purification and cloning of
aggrecanase-1: a member of the ADAMTS family of
proteins. Science 1999;284:1664–6.
10. Lark MW, Bayne EK, Flanagan J, Harper CF, Hoerrner
LA, Hutchinson NI, et al. Aggrecan degradation in
human cartilage. Evidence for both matrix metallo-
proteinase and aggrecanase activity in normal,
osteoarthritic, and rheumatoid joints. J Clin Invest
1997;100:93–106.11. Apte SS, Olsen BR, Murphy G. The gene structure of
tissue inhibitors of metalloproteinases (TIMP)-3 and
its inhibitory activities define the distinct TIMP gene
family. J Biol Chem 1995;270:14313–8.
12. Wolfe GC, MacNaul KL, Buechel FF, McDonnel J,
Hoerrner LA, Lark MW, et al. Differential in vivo
expression of collagenase messenger RNA in syn-
ovium and cartilage: quantitative comparison with
stromelysin messenger RNA levels in human rheu-
matoid arthritis and osteoarthritis patients and in
two animal models of acute inflammatory arthritis.
Arthritis Rheum 1993;36:1540–7.
13. Woessner J. Matrix metalloproteinases and their inhibi-
tors in connective tissue remodeling. FASEB J
1991;5:2145–54.
14. Brinkerhoff CE. Joint destruction in arthritis: metallo-
proteinases in the spotlight. Arthritis Rheum
1991;34:1073–5.
15. Wrana JL, Attisano L, Ca´rcamo J, Zentella A, Doody J,
Laiho M, et al. TGF signals through a heteromeric
protein kinase receptor complex. Cell 1992;71:
1003–14.
16. Malfait AM. Development of an in vitro model to study
cytokine-mediated interactions between inflamma-
tory cells and human chondrocytes. Ghent University
Thesis 1994: p. 45.
17. Almqvist KF, Wang L, Wang J, Baeten D, Cornelissen
M, Verdonk R, et al. Culture of chondrocytes in
alginate surrounded by fibrin gel: characteristics of
the cells over a period of 8 weeks. Ann Rheum Dis
2001;60:781–90.
18. Platt D, Wells T, Bayliss MT. Proteoglycan metabolism
of equine articular chondrocytes cultured in alginate
beads. Res Vet Sci 1997;62:39–47.
19. Green, WT Jr. Behavior of articular chondrocytes in
cell culture. Clin Orthop 1971;75:248–60.
20. Kuettner KE, Pauli BU, Gall G, McMemoli VA, Schenk
RK. Synthsis of cartilage matrix by mammalian
chondrocytes in vitro. Isolation, culture characteris-
tics and morphology. J Cell Biol 1982;93:743–50.
21. Verbruggen G, Veys EM, Wieme N, Malfait AM,
Gijselbrecht L, Nimmegeers J, et al. The synthesis
and immobilisation of cartilage-specific proteoglycan
by human chondrocytes in different concentrations of
agarose. Clin Exp Rheumatol 1990;8:371–8.
22. Benya PD, Shaffer JD. Dedifferentiated chondrocytes
reexpress the differentiated collagen phenotype
when cultured in agarose gels. Cell 1982;30:215–24.
23. Cornelissen M, Verbruggen G, Malfait AM, Veys EM,
Broddelez C, De Ridder L. The study of represen-
tative populations of native aggrecan aggregates
synthesized by human chondrocytes in vitro. J Tiss
Cult Meth 1993;15:139–46.
24. Verbruggen G, Malfait AM, Dewulf M, Broddelez C,
Veys EM. Standardization of nutrient media for
isolated human articular chondrocytes in gelified
agarose suspension culture. Osteoarthritis Cart
1995;3:249–59.
25. Wang L, Verbruggen G, Almqvist KF, Elewaut D,
Broddelez C, Veys EM. Flow cytometric analysis
of the human articular chondrocyte phenotype.
Osteoarthritis Cart 2001;9:73–84.
26. Wang L, Almqvist KF, Broddelez C, Veys EM,
Verbruggen G. Evaluation of chondrocyte cell-
associated matrix metabolism by flow cytometry.
Osteoarthritis Cart 2001;9:454–62.
Osteoarthritis and Cartilage Vol. 10, No. 3 19727. Maroudas A, Mizrahi J, Katz EP, Wachtel EJ, Soudry
M. Physiochemical properties and functional behav-
ior of normal and osteoarthritic human cartilage. In:
Kuettner K, Schleyerbach R, Hascall VC, Peyron JJ,
Eds. Articular Cartilage Biochemistry, 3rd edn. New
York: Raven Press 1986.
28. Boumediene K, Conrozier T, Mathieu P, Richard M,
Marcelli C, Vignon E, et al. Decrease of cartilage
transforming growth factor- receptor II expression in
the rabbit experimental osteoarthritis. Potential role
in cartilage breakdown. Osteoarthritis Cart 1998;6:
146–9.
29. Serra R, Jonson M, Filvaroff EH, Laborde J, Sheehan
DM, Derynck R, et al. Expression of a truncated,
kinase-defective TGF- type II receptor in mouse
skeletal tissue promotes terminal chondrocyte differ-
entiation and osteoarthritis. J Cell Biol 1997;139:
541–52.
30. Scharstuhl A, van der Kraan P, Vitters E, van den Berg
W. In vivo inhibition of TGF- activity by soluble
type II TGF- receptor. Osteoarthritis Cart 2000;
8(Suppl A):S8.
31. Dean DD, Martel-Pelletier J, Pelletier JP, Howell DS,
Woessner JF Jr. Evidence for metalloproteinase and
metalloproteinase inhibitor imbalance in human
osteoarthritic cartilage. Arthritis Rheum 1990;33:
1466–76.
32. Su S, Grover J, Roughley PJ, DiBattista JA, Martel-
Pelletier J, Pelletier JP, et al. Expression of the tissue
inhibitor of metalloproteinases (TIMP) gene family
in normal and osteoarthritic joints. Rheumatol Int
1999;18:183–91.
33. Clark IM, Powell LK, Hazleman BL, Cawston TE.
The measurement of collagenase, TIMP and
collagenase-TIMP complex in synovial fluids from
patients with osteoarthritis and rheumatoid arthritis.
Arthritis Rheum 1993;36:372–9.
34. Cawston TE, Curry V, Ramsey S, Clark IM, Kyle VA,
Adebajo A, et al. The levels of collagenase,
tissue inhibitor of metalloproteinases-1 (TIMP-1),
collagenaseTIMP-1 complexes and glycosamino-
glycan (GAG) in sequential samples of synovial fluid
aspirated from patients with osteoarthritis. Clin Exp
Rheumatol 1995;13:431–7.
35. Ishiguro N, Ito T, Ito H, Iwata H, Jugessur H, Ionescu
M, et al. Relationship of matrix metalloproteinases
and their inhibitors to cartilage proteoglycan and
collagen turnover: analyses of synovial fluid from
patients with osteoarthritis. Arthritis Rheum 1999;42:
129–36.
36. Mitchell PG, Magna HA, Reeves LM, Lopresti-Morrow
LL, Yocum SA, Rosner PJ, et al. Cloning, expression,
and type II collagenolytic activity of matrix
metalloproteinase-13 from human osteoarthritic car-
tilage. J Clin Invest 1996;97:761–8.
37. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A,
Bourne R, Rorabeck C, et al. Enhanced cleavage of
type II collagen by collagenases in osteoarthritic
articular cartilage. J Clin Invest. 1997;99:1534–45.
38. Shlopov BV, Lie WR, Mainardi CL, Cole AA,
Chubinskaya S, Hasty KA. Osteoarthritic lesions:
involvement of three different collagenases. Arthritis
Rheum 1997;40:2065–74.
39. Tortorella M, Pratta M, Liu RQ, Abbaszade I, Ross H,
Burn T, et al. The thrombospondin motif of
aggrecanase-1 (ADAMTS-4) is critical for aggrecansubstrate recognition and cleavage. J Biol Chem
2000;275:25791–7.
40. Hughes CE, Caterson B, Fosang AJ, Roughley PJ,
Mort JS. Monoclonal antibodies that specifically
recognize neoepitope sequences generated by
‘aggrecanase’ and matrix metalloproteinase cleav-
age of aggrecan: application to catabolism in situ and
in vitro. Biochem J 1995;305:799–804.
41. Arner EC, Pratta MA, Trzaskos JM, Decicco CP,
Tortorella MD. Generation and characterization of
aggrecanase. A soluble, cartilage-derived aggrecan-
degrading activity. J Biol Chem 1999;274:6594–601.
42. Bonassar LJ, Sandy JD, Lark MW, Plaas AH, Frank
EH, Grodzinsky AJ. Inhibition of cartilage degra-
dation and changes in physical properties induced
by IL-1beta and retinoic acid using matrix metallo-
proteinase inhibitors. Arch Biochem Biophys 1997;
344: 404–12.
43. Hashimoto G, Aoki T, Nakamura H, Tanzawa K, Okada
Y. Inhibition of ADAMTS4 (aggrecanase-1) by tissue
inhibitors of metalloproteinases (TIMP-1, 2, 3 and 4).
FEBS Lett 2001;494:192–5.
44. Kashiwagi M, Tortorella M, Nagase H, Brew K. TIMP-3
is a potent inhibitor of aggrecanase 1 (ADAM-TS4)
and aggrecanase 2 (ADAM-TS5). J Biol Chem
2001;276:12501–4.
45. Su S, Dehnade F, Zafarullah M. Regulation of tissue
inhibitor of metalloproteinases-3 gene expression by
transforming growth factor-beta and dexamethasone
in bovine and human articular chondrocytes. Cell Biol
1996;15:1039–48.
46. Verbruggen G, Cornelissen M, Almqvist KF, Wang L,
Elewaut D, Broddelez C, et al. Influence of aging
on the synthesis and morphology of the aggrecans
synthesised by differentiated human articular
chondrocytes. Osteoarthritis Cart 2000;8:170–9.
47. Breckon JJW, Hembry RM, Reynolds JJ, Meikle MC.
Identification of matrix metalloproteinases and their
inhibitor in the articular disc of the craniomandibular
joint of the rabbit. Archs oral Biol 1996;41:315–22.
48. Hayakawa T, Yamashita K, Ohuchi E, Shinagawa A.
Cell growth-promoting activity of tissue inhibitor of
metalloproteinases-2 (TIMP-2). J Cell Sci 1994;107:
2373–9.
49. Yang TT, Hawkes SP. Role of the 21-kDa protein
TIMP-3 in oncogenic transformation of cultured
chicken embryo fibroblasts. Proc Natl Acad Sci USA
1992;89:10676–80.
50. Shlopov BV, Smith GN Jr, Cole AA, Hasty KA. Differ-
ential patterns of response to doxycycline and trans-
forming growth factor beta1 in the down-regulation of
collagenases in osteoarthritic and normal human
chondrocytes. Arthritis Rheum 1999;42:719–27.
51. Uria JA, Jimenez G, Balbin M, Freije JM, Lopez-Otin C.
Differential effcts of transforming growth factor-beta
on the expression of collagenase-1 and -3 in human
fibroblasts. J Biol Chem 1998;273:9769–77.
52. Coletta RD, Almeida OP, Reynolds MA, Sauk JJ.
Alteration in expression of MMP-1 and MMP-2 but
not TIMP-1 and TIMP-2 in hereditary gingival
fibromatosis is mediated by TGF-beta 1 autocrine
stimulation. J Periodontal Res 1999;34:457–63.
53. Alvares O, Klebe R, Grant G, Cochran DL. Growth
factor effects on the expression of collagenase and
TIMP-1 in periodontal ligament cells. J Periodontol
1995;66:552–8.
198 L. Wang et al.: TGF- and cartilage extracellular matrix homeostasis54. Tardif G, Pelletier JP, Dupuis M, Geng C, Cloutier JM,
Martel-Pelletier J. Collagenase 3 production by
human osteoarthritic chondrocytes in response togrowth factors and cytokines is a function of the
physiologic state of the cells. Arthritis Rheum
1999;42:1147–58.
